Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto2 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan Purpose: To evaluate the effect of aflibercept treatment after...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miura M, Iwasaki T, Goto H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2d8bb254aaf643469d67269acdc1e29a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d8bb254aaf643469d67269acdc1e29a
record_format	dspace
spelling	oai:doaj.org-article:2d8bb254aaf643469d67269acdc1e29a2021-12-02T02:10:08ZIntravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis1177-54671177-5483https://doaj.org/article/2d8bb254aaf643469d67269acdc1e29a2013-08-01T00:00:00Zhttp://www.dovepress.com/intravitreal-aflibercept-for-polypoidal-choroidal-vasculopathy-after-d-a13938https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto2 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan Purpose: To evaluate the effect of aflibercept treatment after developing ranibizumab tachyphylaxis for the treatment of polypoidal choroidal vasculopathy (PCV). Patients and methods: Ten eyes from ten patients with PCV who developed ranibizumab tachyphylaxis were reviewed. Tachyphylaxis was defined as when repeated intravitreal ranibizumab (IVR) resulted in a complete lack of response after initial treatment response. All treatments were converted to intravitreal aflibercept (IVA) after development of ranibizumab tachyphylaxis. Central retinal thickness (CRT) was compared at baseline, at complete resolution after IVR, at reactivation after IVR, at initial IVA, and at 4 and 12 weeks after initial IVA. Results: Mean number of IVR treatments before conversion to IVA was 11.3 (range 5–16). All eyes had positive therapeutic responses after conversion to IVA. Mean CRT at 4 and 12 weeks after initial IVA was significantly decreased from baseline initial IVA (P = 0.005). Conclusion: Switching therapy to aflibercept is effective for patients with PCV who develop tachyphylaxis to ranibizumab. Keywords: polypoidal choroidal vasculopathy, ranibizumab, aflibercept, tachyphylaxisMiura MIwasaki TGoto HDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1591-1595 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Miura M Iwasaki T Goto H Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
description	Masahiro Miura,1,2 Takuya Iwasaki,1,2 Hiroshi Goto2 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ami, Ibaraki, Japan; 2Department of Ophthalmology, Tokyo Medical University, Nishi-Shinjuku, Tokyo, Japan Purpose: To evaluate the effect of aflibercept treatment after developing ranibizumab tachyphylaxis for the treatment of polypoidal choroidal vasculopathy (PCV). Patients and methods: Ten eyes from ten patients with PCV who developed ranibizumab tachyphylaxis were reviewed. Tachyphylaxis was defined as when repeated intravitreal ranibizumab (IVR) resulted in a complete lack of response after initial treatment response. All treatments were converted to intravitreal aflibercept (IVA) after development of ranibizumab tachyphylaxis. Central retinal thickness (CRT) was compared at baseline, at complete resolution after IVR, at reactivation after IVR, at initial IVA, and at 4 and 12 weeks after initial IVA. Results: Mean number of IVR treatments before conversion to IVA was 11.3 (range 5–16). All eyes had positive therapeutic responses after conversion to IVA. Mean CRT at 4 and 12 weeks after initial IVA was significantly decreased from baseline initial IVA (P = 0.005). Conclusion: Switching therapy to aflibercept is effective for patients with PCV who develop tachyphylaxis to ranibizumab. Keywords: polypoidal choroidal vasculopathy, ranibizumab, aflibercept, tachyphylaxis
format	article
author	Miura M Iwasaki T Goto H
author_facet	Miura M Iwasaki T Goto H
author_sort	Miura M
title	Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
title_short	Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
title_full	Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
title_fullStr	Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
title_full_unstemmed	Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
title_sort	intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/2d8bb254aaf643469d67269acdc1e29a
work_keys_str_mv	AT miuram intravitrealafliberceptforpolypoidalchoroidalvasculopathyafterdevelopingranibizumabtachyphylaxis AT iwasakit intravitrealafliberceptforpolypoidalchoroidalvasculopathyafterdevelopingranibizumabtachyphylaxis AT gotoh intravitrealafliberceptforpolypoidalchoroidalvasculopathyafterdevelopingranibizumabtachyphylaxis
_version_	1718402638954889216

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis

Ejemplares similares